Pelthos Therapeutics (PTHS) Drops -35% Over 30 Days as ZELSUVMI Launch Pressures Mount

Key Takeaways

• Pelthos Therapeutics (PTHS) has fallen roughly 35% over the last 30 days, sliding from a closing price near $22.19 in late September to about $14.50.
• The decline extends a longer downtrend: the shares have shed nearly half their value over the trailing three months, retreating from the high-$20s range in late July.
• Key pressures include a wider-than-expected second-quarter loss, decelerating ZELSUVMI prescription growth, and a series of analyst price-target reductions.
• Commercial execution remains the central theme, with investors weighing the ZELSUVMI launch trajectory against rising spending and cash-burn concerns.
• A new Pharmacy Benefit Manager agreement covering roughly 24 million lives, announced in early October, has expanded ZELSUVMI access but has yet to stabilize the share price.

Company Background and Current Focus

Pelthos Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on dermatology and pediatric infectious disease. Its lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is approved for the treatment of molluscum contagiosum in adults and pediatric patients one year of age and older. The company's broader portfolio includes XEPI, a quinolone antimicrobial for impetigo, and XEGLYZE, a pediculicide for head lice, as well as a clinical-stage NaV 1.7 program built on its proprietary NITRICIL nitric-oxide technology platform.

Because ZELSUVMI launched commercially only in July 2025, investors follow PTHS closely for evidence of prescription uptake, payer and formulary access, and the company's progress toward revenue scale and profitability. As a small-cap biotech with a limited float, the stock also tends to exhibit above-average volatility relative to the broader market. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Recent Stock Performance: 30 Days and the Broader Quarter

Over the last 30 days, PTHS has declined approximately 35%. The stock closed near $22.19 on September 25, 2026, and subsequently trended lower through October, accelerating in the final weeks of the month to trade around $14.50.

The move is part of a broader slide rather than an isolated event. Over the trailing quarter, the shares have fallen roughly 45%, coming down from the high-$20s range in late July. The decline has been persistent but punctuated by sharper selloffs, most notably in late October, when the stock dropped from about $20.50 to the mid-teens in a matter of days.

Factors Behind the 30-Day Decline

The recent downturn reflects a combination of fundamental and sentiment-driven factors. Second-quarter 2026 results, reported in August, showed strong top-line momentum — net product revenue rose 45% to $15.4 million and ZELSUVMI prescription units grew 48% to 11,925 — but the company posted a wider-than-expected loss, with earnings per share of -$6.62 against a consensus estimate of roughly -$0.51.

Since then, Wall Street has steadily reset its assumptions. Analysts at Alliance Global lowered their price target from $45 to $30, and Lake Street reduced its target from $50 to $40, both citing softer ZELSUVMI prescription trends and slower-than-hoped growth. The average analyst fair-value estimate has slipped from about $59.80 to roughly $51.71 per share, reflecting more cautious launch and spending assumptions.

On the positive side, Pelthos announced in early October that it had signed an agreement with a major Pharmacy Benefit Manager to open access to ZELSUVMI, reaching approximately 24 million additional covered lives. The company reported formulary coverage across roughly 127 million, or 69%, of commercially covered lives. Despite this expanded access, investor concerns about slowing prescription momentum have outweighed the headline, keeping the shares under pressure.

Quarterly Context and Shifting Narratives

The multi-month decline reflects a larger narrative shift around the ZELSUVMI launch. Earlier in 2026, analyst commentary highlighted a strong first year of commercialization, with several firms describing the first four quarters of the launch as a robust start. Over the summer, however, attention turned to whether growth was beginning to decelerate, with analysts noting that the anticipated back-to-school seasonal bump had not fully materialized.

The repeated reductions in price targets — from Oppenheimer, Alliance Global, and Lake Street — signal a broad reassessment of execution and required investment rather than a single negative event. Combined with a small-cap capital structure, elevated beta, and a reliance on one lead product, this shift in expectations has translated into sustained downward pressure on the shares throughout the quarter.

Key Areas to Monitor Going Forward

Looking ahead, investors are likely to focus on third-quarter prescription data and the next earnings update as the clearest signals of whether ZELSUVMI growth is stabilizing or continuing to slow. Payer and formulary progress, including the integration of the recent PBM agreement, will be central to the revenue outlook, as will gross margin trends and the pace of cash consumption.

Analyst expectations have already been recalibrated lower, so any evidence of reacceleration in prescriptions or improved net pricing could matter more than headline revenue. Conversely, further execution setbacks, competitive developments in dermatology, or an acceleration in cash burn would present additional risks. As with any small-cap biopharmaceutical name, price moves can be amplified by limited liquidity and concentrated institutional positioning. From what I see, this is important because it highlights how sensitive the stock remains to execution milestones.

Using AI Tools in My Research Process

In my ongoing analysis of names like PTHS, I frequently turn to Tickeron’s AI Daily Buy/Sell Signals to cross-check momentum indicators and compare signals across the sector. This helps me stay objective when fundamentals and sentiment appear to be pulling in different directions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume